| --- | --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | Pacira BioSciences | | | | | | | Corporate Presentation February 2022 | | | | | | Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans, ...

Pacira BioSciences (NASDAQ: PCRX) Corporate Presentation November 2021 Forward-looking statements and where to find additional information Any statements in this communication about Pacira BioSciences, Inc.'s ("Pacira") or Flexion Therapeutics, Inc.'s ("Flexion") future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incor ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants Susan Mesco - IR Dave Stack - Chairman and CEO Charlie Reinhart - CFO Ronald Ellis - Senior Vice President Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets David Steinberg - Jefferies Balaji Prasad - Barclays Greg Fraser - Truist Securities Anita Dushyanth - Berenberg Capital Christopher Neyor - JPMorgan Serge Belanger - Needham & Company And ...

Pacira BioSciences (NASDAQ: PCRX) Corporate Presentation August 2021 Forward-looking statements 2 Any statements in this presentation about the company's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1 ...

Q2 2021 Commercial Metrics Overview August 4, 2021 Commercial Overview: Q2 Performance Metrics $30.0 $25.0 $20.0 $15.0 $10.0 $5.0 $- $24.6 $28.2 $- $5.0 $10.0 $15.0 $20.0 $25.0 $30.0 Q1 2021 Q2 2021 Net Sales - Current vs Prior Qtr Dollars in millions 15% 36,697 56,798 - 10,000 20,000 30,000 40,000 50,000 60,000 Q2 2020 Q2 2021 Demand - Current vs Same Qtr Prior Year 55% Zilretta Units 53,089 56,798 - 10,000 20,000 30,000 40,000 50,000 60,000 Q1 2021 Q2 2021 Demand - Current vs Prior Qtr Zilretta Units 7% $ ...

Flexion Therapeutics, Inc. (FLXN) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications and Investor Relations Michael Clayman - Chief Executive Officer Melissa Layman - Chief Commercial Officer Fred Driscoll - Chief Financial Officer Conference Call Participants Michael Pagliari - Raymond James Madhu Kumar - Goldman Sachs Daniel Busby - RBC Capital Markets Evan Hua - BMO Capital Markets Serge Belanger - Needham & Company Patri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (I.R.S. Employer Ident ...

Q1 2021 Commercial Metrics Overview May 12, 2021 Commercial Overview: Q1 Performance Metrics $24.6 Q1 2020 Q1 2021 Net Sales - Current vs Same Qtr Prior Year Dollars in millions 22% $26.3 $24.6 Q4 2020 Q1 2021 Net Sales - Current vs Prior Qtr Dollars in millions -7% 6% $20.1 36,543 53,089 Q1 2020 Q1 2021 Demand - Current vs Same Qtr Prior Year 45% Zilretta Units 50,056 53,089 Q4 2020 Q1 2021 Zilretta Units Demand - Current vs Prior Qtr • ZILRETTA® net sales of $24.6 million in Q1 2021 • In Q1 2,044 accounts ...

Flexion Therapeutics, Inc. (FLXN) Q1 2021 Earnings Conference Call May 12, 2021 4:30 AM ET Company Participants Scott Young - VP of Corporate Communications & Investor Relations Michael Clayman - CEO Melissa Layman - Chief Commercial Officer David Arkowitz - CFO Fred Driscoll - Incoming CFO Conference Call Participants Elliot Wilbur - Raymond James Madhu Kumar - Goldman Sachs Serge Belanger - Needham & Company Evan Hua - BMO Capital Markets Patrick Trucchio - H.C. Wainwright François Brisebois - Oppenheimer ...